Evidence map›Paper›PMID 24848797›Full record

ArticleToxicological sciences : an official journal of the Society of Toxicology2014

A systems biology approach utilizing a mouse diversity panel identifies genetic differences influencing isoniazid-induced microvesicular steatosis.

Rachel J Church, Hong Wu, Merrie Mosedale, Susan J Sumner, Wimal Pathmasiri, Catherine L Kurtz, Mathew T Pletcher, John S Eaddy, Karamjeet Pandher, Monica Singer and 4 more

Open access · bronzeAbstract read
In one paragraph

Article in Toxicological sciences : an official journal of the Society of Toxicology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
5.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 54 citations in OpenAlex.

  1. Natural variation suggests candidate genes underlying Caenorhabditis elegans susceptibility to diverse toxicants.Toxicological sciences : an official journal of the Society of Toxicology · 2026
    Article
  2. Natural variation suggests candidate genes underlyingbioRxiv : the preprint server for biology · 2025
    Article
  3. Article
  4. Lansoprazole Ameliorates Isoniazid-Induced Liver Injury.Pharmaceuticals (Basel, Switzerland) · 2024
    Article
  5. Review
  6. Drug delivery systems for RNA therapeutics.Nature reviews. Genetics · 2022
    Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Clinical perspectives of isoniazid-induced liver injury.Liver research (Beijing, China) · 2021
    Review
  12. Identification of Candidate Risk Factor Genes for Human Idelalisib Toxicity Using a Collaborative Cross Approach.Toxicological sciences : an official journal of the Society of Toxicology · 2019
    Article
  13. Article
  14. Genetic determinants of susceptibility to silver nanoparticle-induced acute lung inflammation in mice.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2017
    Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 1 country.

Rachel J ChurchHamner-University of North Carolina Institute for Drug Safety Sciences, The Hamner Institutes for Health Sciences, Research Triangle Park, North Carolina 27709 ahharrill@uams.edu.
Hong WuDrug Safety Research and Development, Pfizer Global Research and Development, Groton, Connecticut 06340 ahharrill@uams.edu.
Merrie MosedaleHamner-University of North Carolina Institute for Drug Safety Sciences, The Hamner Institutes for Health Sciences, Research Triangle Park, North Carolina 27709 ahharrill@uams.edu.
Susan J SumnerDiscovery Sciences, RTI International, Research Triangle Park, North Carolina 27709.
Wimal PathmasiriDiscovery Sciences, RTI International, Research Triangle Park, North Carolina 27709.
Catherine L KurtzHamner-University of North Carolina Institute for Drug Safety Sciences, The Hamner Institutes for Health Sciences, Research Triangle Park, North Carolina 27709.
Mathew T PletcherDrug Safety Research and Development, Pfizer Global Research and Development, Groton, Connecticut 06340.
John S EaddyHamner-University of North Carolina Institute for Drug Safety Sciences, The Hamner Institutes for Health Sciences, Research Triangle Park, North Carolina 27709.
Karamjeet PandherDrug Safety Research and Development, Pfizer Global Research and Development, Groton, Connecticut 06340.
Monica SingerJanssen Research and Development, Drug Safety Sciences, Raritan, New Jersey 08869.
Ameesha BathejaJanssen Research and Development, Drug Safety Sciences, Raritan, New Jersey 08869.
Paul B WatkinsHamner-University of North Carolina Institute for Drug Safety Sciences, The Hamner Institutes for Health Sciences, Research Triangle Park, North Carolina 27709 Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 School of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599.
Karissa AdkinsDrug Safety Research and Development, Pfizer Global Research and Development, Groton, Connecticut 06340 ahharrill@uams.edu.
Alison H HarrillHamner-University of North Carolina Institute for Drug Safety Sciences, The Hamner Institutes for Health Sciences, Research Triangle Park, North Carolina 27709 Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 The University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205 ahharrill@uams.edu.
Pfizer (United States) · USThe Hamner Institutes for Health Sciences · USResearch Triangle Park Foundation · USJanssen (United States) · USUniversity of Arkansas for Medical Sciences · US

Funding

RTI's Regional Comprehensive Metabolomics Resource CenterU24DK097193 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI SUMNER, SUSAN J · 2012 to 2017
$9.8M
NIDDK NIH HHS U24 DK097193
6 · The paper itself

Abstract

Isoniazid (INH), the mainstay therapeutic for tuberculosis infection, has been associated with rare but serious hepatotoxicity in the clinic. However, the mechanisms underlying inter-individual variability in the response to this drug have remained elusive. A genetically diverse mouse population model in combination with a systems biology approach was utilized to identify transcriptional changes, INH-responsive metabolites, and gene variants that contribute to the liver response in genetically sensitive individuals. Sensitive mouse strains developed severe microvesicular steatosis compared with corresponding vehicle control mice following 3 days of oral treatment with INH. Genes involved in mitochondrial dysfunction were enriched among liver transcripts altered with INH treatment. Those associated with INH treatment and susceptibility to INH-induced steatosis in the liver included apolipoprotein A-IV, lysosomal-associated membrane protein 1, and choline phosphotransferase 1. These alterations were accompanied by metabolomic changes including reduced levels of glutathione and the choline metabolites betaine and phosphocholine, suggesting that oxidative stress and reduced lipid export may additionally contribute to INH-induced steatosis. Finally, genome-wide association mapping revealed that polymorphisms in perilipin 2 were linked to increased triglyceride levels following INH treatment, implicating a role for inter-individual differences in lipid packaging in the susceptibility to INH-induced steatosis. Taken together, our data suggest that INH-induced steatosis is caused by not one, but multiple events involving lipid retention in the livers of genetically sensitive individuals. This work also highlights the value of using a mouse diversity panel to investigate drug-induced responses across a diverse population.

Indexed as

Systems BiologyAnimalsAntitubercular AgentsCholesterolFatty LiverFemaleGene ExpressionIsoniazidLiverMembrane ProteinsMetabolomicsMiceMice, Inbred StrainsPerilipin-2Polymorphism, Single NucleotideAntitubercular AgentsCholesterolIsoniazidMembrane ProteinsPerilipin-2

Identifiers

PMID24848797
PMCPMC4168290
OpenAlexW2108572417

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.